Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Addex Therapeutics ( (CH:ADXN) ).
Addex Therapeutics reported steady progress across its pipeline in 2025, advancing a GABAB PAM candidate for chronic cough through preclinical development and preparing dipraglurant for clinical studies in post-stroke and traumatic brain injury recovery. The company also entered an option and collaboration deal with Sinntaxis to secure intellectual property for mGlu5 NAM use in brain injury recovery and regained full rights to its Phase 2 mGlu2 PAM asset ADX71149.
Strategically, Addex’s partner Indivior moved a GABAB PAM candidate for substance use disorders through IND-enabling studies, while Addex deepened its exposure to innovative neurotherapies via a strategic investment in Stalicla and maintained a 20% stake in spin-out Neurosterix. Financially, Addex swung to a net loss of CHF 6.7 million from a prior-year profit largely due to one-off 2024 divestment gains, saw cash fall to CHF 1.6 million, and recorded higher losses from associates, underscoring its reliance on partnerships and external financing as it advances its neurology-focused pipeline.
More about Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule allosteric modulators targeting neurological disorders. Its lead candidate is dipraglurant, an mGlu5 negative allosteric modulator being repositioned for brain injury recovery, while partnered and in-house GABAB positive allosteric modulator programs address substance use disorders and chronic cough.
Average Trading Volume: 229,467
Technical Sentiment Signal: Sell
Current Market Cap: CHF7.25M
See more data about ADXN stock on TipRanks’ Stock Analysis page.